search
Highlights
     // . //  Oliver Wyman Health //  Managing Uncertainties In Cell And Gene Therapy Supply Chain

    Managing Uncertainties In Cell And Gene Therapy Supply Chain

    Image

    Since the infrastructure needed to support cell and gene therapies is so complex, companies must assess supply chain issues early, even before entering human studies.

    Tobias Handschuh and Matthew Lakelin

    2 min read

    Table of Contents

      Begin with the end in mind. That’s Matthew Lakelin’s advice for companies aiming to bring cell and gene therapies to market.

      Because the infrastructure needed to support cell and gene therapies is so complex, companies must consider supply chain issues very early on, even before they enter human studies, said Lakelin, Vice President of Scientific Affairs at TrakCel, a company that helps manage all components of the cell and gene therapy supply chain.

      For instance, blood, tissue, and other materials used in cell and gene therapy may have time and temperature constraints. Any misstep in the supply chain means starting over. Those factors will impact where manufacturing plants are built, which logistics companies are involved in transporting materials, how far a clinic or treatment site is from the plant and the patient.

      In this video, Lakelin and Oliver Wyman’s Tobias Handschuh detail what’s required to ensure that cell and gene therapies can get to patients in a safe, efficient, and timely manner. The interview was recorded at the Oliver Wyman Health and Life Sciences Innovation Forum.

      8:08

      Authors

      Bringing Value-Based Care To Rural America

      By leveraging technology, in-home patient visits, and mobile clinics, Homeward Health is out to prove the value-based care can work in rural communities.

      RSV Will Be The New Battleground For Vaccines Manufacturers

      Two RSV vaccines have been approved and the industry can leverage learnings from flu and COVID protocols to prevent a tripledemic from overwhelming the system.

      Will The Smartwatch Transform Diabetes Management?

      With non-invasive continuous glucose monitoring solutions on the horizon, medtech companies have an opportunity to help diabetes patients manage their disease.

      Pharma’s Opportunity To Impact Health Equity

      Pharmaceutical companies are uniquely positioned to impact health equity. It must become a corporate priority and engrained in the product life cycle.